Replies to post #211563 on Biotech Values

[DewDiligence]

MRK still trying to be relevant in HIV without a single-tablet regimen—reports phase-3 results for NNRTI, Doravine:

https://finance.yahoo.com/news/merck-announces-week-96-data-104500725.html